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Obesity, type 2 diabetes, and heart failure are associ-
ated with aberrant cardiac metabolism. We show
that the heart regulates systemic energy homeo-
stasis via MED13, a subunit of the Mediator complex,
which controls transcription by thyroid hormone
and other nuclear hormone receptors. MED13, in
turn, is negatively regulated by a heart-specific mi-
croRNA, miR-208a. Cardiac-specific overexpression
of MED13 or pharmacologic inhibition of miR-208a in
mice confers resistance to high-fat diet-induced
obesity and improves systemic insulin sensitivity
and glucose tolerance. Conversely, genetic deletion
of MED13 specifically in cardiomyocytes enhances
obesity in response to high-fat diet and exacerbates
metabolic syndrome. The metabolic actions of
MED13 result from increased energy expenditure
and regulation of numerous genes involved in energy
balance in the heart. These findings reveal a role of
the heart in systemic metabolic control and point to
MED13 and miR-208a as potential therapeutic
targets for metabolic disorders.
INTRODUCTION
Maintaining energy homeostasis requires a balance between
energy consumption and energy expenditure. Excess food
consumptionshiftsenergybalance,causingobesity,amultiorgan
disorder that enhances the risk of type 2 diabetes, hypertension,
hyperlipidemia, and cardiovascular disease (Van Gaal et al.,
2006). Impaired metabolism of energy-providing substrates and
myocardial lipid accumulation are early abnormalities in obese
and insulin-resistant individuals (Harmancey et al., 2008).
The heart adapts to changes in diet and stress by fine-tuning
metabolism and gene expression patterns to maximize energy
efficiency (Balaban et al., 1986). Thyroid hormone (TH) receptors
(TRs) and other nuclear receptors (NRs) are key regulators ofenergy homeostasis in the heart and other tissues (Huss and
Kelly, 2004). Activation of TRs directly through elevation of TH
results in enhanced energy expenditure and a lean phenotype
(Mitchell et al., 2010; Watanabe et al., 2006). Numerous genes
involved in energy balance are controlled by TH-responsive
elements (TREs) and are directly activated or repressed by TRs
(Song et al., 2011). Other nuclear hormone receptors, such as
PPARs and retinoid X receptor (RXR), as well as their coactiva-
tors and corepressors, also control energy homeostasis by
activation of lipogenic genes in the heart and other tissues
(Huss and Kelly, 2004).
Recent studies have revealed important roles for microRNAs
(miRNAs) in heart disease (Latronico and Condorelli, 2009;
van Rooij et al., 2007) and metabolism (Frost and Olson, 2011;
Trajkovski et al., 2011). miRNAs inhibit protein expression
through base-pairing with sequences located predominantly in
the 30 untranslated regions (UTRs) of mRNA targets (Bartel,
2004). The functions of miRNAs often become pronounced
under conditions of stress, making them potential targets for
disease modulation (Small and Olson, 2011).
MiR-208a is a cardiac-specific miRNA encoded by an intron
of the cardiac-specific a-myosin heavy-chain (MHC) gene.MiR-
208a/ mice do not display overt abnormalities at baseline, but
hearts from these mice are resistant to pathological remodeling
and fibrosis and do not upregulate b-MHC, a marker of cardiac
stress, in response to pressure overload or hypothyroidism
(Callis et al., 2009; vanRooij et al., 2007). Pharmacologic inhibition
of miR-208a with locked nucleic acid (LNA)-modified antisense
oligonucleotides also enhances cardiac function and prolongs
survival in a rat model of diastolic dysfunction (Montgomery
et al., 2011). MiR-208a/ hearts resemble hyperthyroid hearts,
which are also protected against pathological hypertrophy and
fibrosis and show diminished b-MHC expression (Tancevski
et al., 2011; van Rooij et al., 2007). These findings suggest that
miR-208a acts, at least in part, by repressing a common com-
ponent of stress-responsive and TH-signaling pathways in the
heart. Among the strongest predicted and validated targets of
miR-208a is MED13/THRAP1/TRAP240 (Callis et al., 2009; van
Rooij et al., 2007), a component of the Mediator complex, which
modulates TH-dependent transcription (Ito and Roeder, 2001).Cell 149, 671–683, April 27, 2012 ª2012 Elsevier Inc. 671
The Mediator is a multiprotein complex that acts as a bridge
between DNA-bound transcription factors and RNA polymerase
II (Conaway andConaway, 2011;Malik andRoeder, 2010).Medi-
ator is composed of 30 subunits, which directly regulate
nuclear hormone receptor-dependent transcription of select
target genes (Ge et al., 2002; Malik and Roeder, 2005; Park
et al., 2005). The activity of the Mediator complex is modulated
by association with a tetrameric regulatory complex called the
kinase submodule, comprised of MED12, MED13, cyclin C,
and cyclin-dependent kinase 8 (CDK8) (Akoulitchev et al.,
2000; Knuesel et al., 2009; Taatjes, 2010).
MED1, a core protein of the Mediator complex, binds directly
to NRs and is necessary for maintaining energy homeostasis in
skeletal muscle (Baek et al., 2002; Chen et al., 2010). Other
components of the Mediator complex also regulate pathways
involved in fatty acid, cholesterol, and lipid homeostasis (Taubert
et al., 2006; Wang et al., 2009; Yang et al., 2006). Recently,
MED13 was identified in Drosophila as a negative regulator of
lipid accumulation, such that its knockdown using siRNA caused
excessive adiposity (Pospisilik et al., 2010).
The potential functions of MED13 or other components of the
Mediator complex in the heart have not been explored. Here, we
used pharmacological and genetic tools to modulate the expres-
sion of miR-208a and its target, MED13, in the heart. We show
that mice with increased cardiac expression of MED13 are lean
and display an increase in energy expenditure and resistance
to diet-induced obesity and metabolic syndrome. Remarkably,
pharmacologic inhibition of miR-208a confers a similar meta-
bolic phenotype. Conversely, cardiac deletion of MED13
increases susceptibility to diet-induced obesity and metabolic
syndrome. Metabolic control by MED13 is associated with
altered expression of a collection of TH- and NR-responsive
genes in the heart. Our results delineate a genetic pathway
whereby MED13 and miR-208a function in the heart to control
whole-bodymetabolism and unveil a role of the heart in systemic
energy homeostasis.
RESULTS
Pharmacologic Inhibition of miR-208a Confers
Resistance to Obesity
While studying the potential therapeutic effects of miR-208a
inhibitors in mice, we noticed that animals treated over a period
of several weeks with LNA antimiR-208a were leaner than litter-
mates either untreated or treated with control oligonucleotides.
Subcutaneous delivery of antimiR-208a (Montgomery et al.,
2011) efficiently inhibited miR-208a levels in the heart, as de-
tected by northern blot analysis (Figure 1A). Treatment of mice
for 6 weeks with antimiR-208a or a control antimiR had no effect
on heart weight, cardiac contractility, or heart rate (Figures S1A–
S1C available online).
To investigate the metabolic basis of the lean phenotype, we
tested the effect of antimiR-208a on weight gain in response
to high-fat (HF) diet. Male mice on HF diet treated with control
antimiR increased their body weight by 75% within 6 weeks,
whereas antimiR-208a-treated mice on HF diet showed only
a 29% increase in body weight (Figures 1B and 1C), which was
comparable to mice maintained on normal chow (NC) and672 Cell 149, 671–683, April 27, 2012 ª2012 Elsevier Inc.treated with control oligonucleotide or antimiR-208a. NMR
spectrometry revealed that the difference in weight between
the treatment groups was due to differences in fat weight
(Figure 1D). Consistent with these findings, visceral white
adipose and subscapular adipose tissue, containing both white
and brown fat, were significantly smaller in antimiR-208a
treatment groups on HF diet and NC compared to the control
antimiR-treated animals, based on fat mass and adipocyte size
(Figures 1E–1G and S1D). Serum triglyceride and cholesterol
levels were also reduced in antimiR-208a-treated mice on HF
diet (Figures 1H and 1I). Similarly, hepatic steatosis seen in
control animals on HF diet was blunted by treatment with anti-
miR-208a (Figure S1D).
HF diet-induced obesity causes glucose intolerance. AntimiR-
208a-treatedmice onNC showed a normal glucose response, as
measured by glucose tolerance test (GTT) (Figure 1J). On HF
diet, control antimiR-treated obese mice displayed an increase
in fat mass and glucose intolerance (Figures 1E and 1J). In
contrast, antimiR-208a-treated mice showed a normal glucose
response after 6 weeks of HF diet, as revealed by GTT and the
calculated area under the curve (Figures 1J and 1K). Fasting
insulin levels from antimiR-208a-treated mice were significantly
lower than those of control antimiR-treated mice (Figure 1L).
Similarly, levels of leptin, an adipocyte-derived circulating
hormone that reflects body lipid content (Frederich et al.,
1995), were reduced by antimiR-208a compared to control anti-
miR in animals on NC and HF diet (Figure 1M). AntimiR-208a
had no effect on food consumption or physical activity (Figures
S1E and S1F). These findings suggested that miR-208a inhibi-
tion improves whole-body insulin sensitivity. Because miR-
208a is only expressed in cardiomyocytes (Callis et al., 2009;
van Rooij et al., 2007), the beneficial metabolic effects of anti-
miR-208a suggested a potential influence of the heart on
systemic metabolism.
Cardiac Overexpression of MED13 Prevents Obesity
and Improves Glucose Homeostasis
The Mediator subunit MED13 is among the strongest predicted
and validated targets of miR-208a. Accordingly, MED13 expres-
sion was increased in hearts of mice treated with antimiR-208a
(Figure S1G). To determine whether elevation of MED13 in the
heart might evoke systemic metabolic effects analogous to
those of miR-208a inhibition, we generated transgenic mice
using the aMHC promoter to overexpress MED13 specifically
in cardiomyocytes. Two independent aMHC-Med13 transgenic
(TG) mouse lines, referred to as lines 1 and 2, showing 9- and
3-fold increases, respectively, in expression of Med13 mRNA
and protein compared to wild-type (WT) in the heart were gener-
ated (Figures S2A and S2B). Neither aMHC-Med13 TG mouse
line showed overt abnormalities. Gross cardiac structure was
also normal, and cardiac stress markers were not elevated in
these mice (Figures S2C and S2D).
Although male aMHC-Med13 TG mice were comparable in
length to WT littermates, they were lighter when fed NC and
were resistant to obesity on HF diet, gaining body weight simi-
larly to WT mice on NC (Figures 2A, 2B, S2E, and S2F). Female
aMHC-Med13 TG mice also displayed resistance to weight
gain on HF diet (Figure S2G). The aMHC-Med13 TG mice had
Figure 1. Mice Administered AntimiR-208a Are Resistant to Obesity and Glucose Intolerance
AntimiR-208a- or control antimiR-treated mice on NC or HF diet for 6 weeks.
(A) Northern blot analysis of mice treated for 6 weeks with antimiR-208a or control antimiR (control). U6 RNA was detected as a loading control. Hearts from five
mice from each treatment were analyzed. Note the absence of miR-208a in antimiR-208a-treated hearts.
(B) Pictures of mice treated for 6 weeks with antimiR on NC or HF diet.
(C) Growth curves and percentage increase in body weight.
(D) Body composition measured by NMR to determine fat mass and lean tissue mass.
(E) Weight of visceral WAT and subscapular BAT.
(F) Hematoxylin and eosin (H&E) stain of visceral WAT and subscapular BAT. Scale bar, 40 mm.
(G) Cell size of visceral WAT. n = 5. Images from three sections 200 mm apart were analyzed from seven to eight mice in each group, representing > 500 cells.
(H) Serum triglyceride levels. n = 5.
(I) Serum cholesterol levels. n = 5.
(J) Glucose tolerance test (GTT).
(K) Area under the curve (A.U.C.) for GTT.
(L and M) Fasting insulin and leptin levels.
Data are represented as mean ± SEM. n = 5 for NC and n = 13 for HF diet for all experiments unless otherwise stated. *p < 0.05.
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Figure 2. aMHC-Med13 TG Mice Are Resistant to Diet-Induced Obesity with Improved Glucose Tolerance
Male aMHC-Med13 TG mice (Line 1) and WT littermates on NC or HF diet for 6 weeks. n = 8–10 unless otherwise stated.
(A) Pictures of WT and aMHC-Med13 TG mice after 6 weeks on NC or HF diet.
(B) Growth curves and percentage increase in body weight.
(C) Body composition measured by NMR to determine fat mass and lean tissue mass.
(D) Weight of visceral WAT and subscapular BAT.
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Figure 3. aMHC-Med13TGMiceHave IncreasedEnergyExpenditure
Twelve-week-old male aMHC-Med13 TG (Line 1) and WT mice on NC were
analyzed in metabolic cages over 4.5 days. n = 8–9.
(A) Food consumption.
(B) Physical activity and average beambreaks in the x, y, and z axis over a 12 hr
light/dark cycle.
(C) Average oxygen consumption per hour during the light/dark cycle (left);
average traces (right) normalized to lean mass.
(D) Average carbon dioxide production per hour during the light/dark cycle
(left); averages traces (right) normalized to lean mass.
Data are represented as mean ± SEM. *p < 0.05 versus WT.significantly less fat mass on both the NC and HF diet compared
to WT littermates, as measured by NMR (Figure 2C). Visceral
WAT and subscapular BAT mass, as well as adipocyte size,
from the aMHC-Med13 TG mice on HF diet and NC were also
reduced compared to WT mice (Figures 2D–2F). Gross and
histological analysis of subscapular fat from aMHC-Med13 TG
mice showed less lipid accumulation on NC and HF diet
compared to WT mice (Figures 2E–2F). WT mice accumulate
fat with age when maintained on NC. aMHC-Med13 TG mice
at 7 and 12 months of age also had significantly less fat mass
than WT littermates (Figure S2H).(E) H&E stain of visceral WAT and subscapular BAT. Scale bar, 40 mm.
(F) Cell size of visceral WAT. Values represent the mean cross-section area of ea
eight mice in each group, representing > 500 cells.
(G–I) Heart, liver, and serum triglyceride levels.
(J) Serum cholesterol levels.
(K) Glucose tolerance test (GTT).
(L) Area under the curve for the GTT.
(M and N) Fasting insulin and leptin levels.
(O) Growth curve showing body weight measured weekly for 5 weeks of ob/ob;
(P) GTT of ob/ob; aMHC-Med13 TG mice compared to ob/ob littermates followi
Data are represented as mean ± SEM. *p < 0.05.Hearts from WT and aMHC-Med13 TG mice on NC or HF
diet showed no differences in lipid accumulation based on oil
red O staining (Figure S2I) or triglyceride levels (Figure 2G).
However, hepatic lipid and triglyceride accumulation were highly
elevated in WT mice on HF diet but were not significantly
different from WT mice on NC in aMHC-Med13 TG mice (Fig-
ures 2H and S2I). Serum triglyceride and cholesterol levels
were also diminished in aMHC-Med13 TG mice compared to
WT on HF diet (Figures 2I and 2J). In addition, aMHC-Med13
TG mice showed a normal glucose response after 6 weeks of
HF diet compared to the glucose intolerance seen in WT mice
(Figures 2K and 2L). Fasting insulin and leptin levels in aMHC-
Med13 TG mice on NC were comparable to those of WT litter-
mates (Figures 2M and 2N), together indicating that elevated
cardiac expression of Med13 improves whole-body insulin
sensitivity.
We bred aMHC-Med13 TG mice with leptin-deficient ob/ob
mice, which become morbidly obese and develop insulin resis-
tance due to the absence of leptin (Tartaglia et al., 1995). Cardiac
overexpression of MED13 reduced weight gain and improved
glucose tolerance in ob/ob mice (Figures 2O and 2P).
MED13 Regulates Energy Consumption
The resistance to weight gain by aMHC-Med13 TGmice was not
due to a difference in food consumption or physical activity
compared to WT mice, as measured using metabolic chambers
(Figures 3A and 3B). Similarly, telemetry revealed no difference in
core body temperature of aMHC-Med13 TG mice compared to
WT littermate controls (Figure S3). Remarkably, however, lean
weight-matched aMHC-Med13 TG mice exhibited an increase
in oxygen consumption and carbon dioxide production, sug-
gesting that the observed decrease in fat mass was due to an
increase in systemic energy consumption mediated by overex-
pression of MED13 in the heart (Figures 3C and 3D).
Downregulation of Nuclear Hormone Receptor Target
Genes by MED13
To further explore the molecular basis of the changes in energy
homeostasis caused by cardiac overexpression of MED13, we
performed microarray analysis on hearts from aMHC-Med13
TG and WT mice. We identified 34 genes upregulated and 62
genes downregulated in aMHC-Med13 TG hearts, with a cutoff
of 2-fold (Figure 4A). Real-time RT-PCR validated these results
(Figure 4B). Upregulated genes in aMHC-Med13 TG hearts
did not appear to fit a specific pattern, whereas the majority of
downregulated genes were involved in metabolism and regu-
lated by NRs (Figures 4A and 4C). Metabolic genes that werech cell. Images from three sections 200 mm apart were analyzed from seven to
aMHC-Med13 TG mice compared to ob/ob littermates. n = 5–7.
ng an overnight fast using 1 mg of glucose/gram body weight. n = 5–7.
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Figure 4. Changes in Cardiac Gene Expression in
aMHC-Med13 TG Mice
(A) Microarray analysis of genes downregulated in hearts
from adult aMHC-Med13 TG mice compared to WT mice.
Orange bars represent genes regulated by nuclear
hormone receptors; purple bars represent genes regu-
lated in diabetes or obesity. Blue bars represent genes
regulated by nuclear hormone receptors and are also
involved in diabetes or obesity.
(B) Real-time qPCR of select genes identified in (A)
comparing aMHC-Med13 TG and WT mice. n = 4–5. Data
are represented as mean ± SEM. *p < 0.05 versus WT.
(C) Ingenuity pathway analysis of genes regulated > 1.5-
fold in the aMHC-Med13 TG mouse array. Highlighted
within the diagram are transcription factors that function
as nodal points for genes regulated in aMHC-Med13 TG
mouse hearts.downregulated in aMHC-Med13 TG hearts were also downregu-
lated in hearts of mice treated with antimiR-208a (Figure S1H).
The Ingenuity Pathways Analysis application (http://www.
ingenuity.com), which identifies molecular relationships among
genes, revealed that many of the downregulated genes in
aMHC-Med13 TG hearts are known targets of NRs (TR, RXR,
LXR), consistent with the repressive influence of MED13 on NR676 Cell 149, 671–683, April 27, 2012 ª2012 Elsevier Inc.activity (Figure 4C). Other transcription factors
that are involved in metabolic regulation
(PPARg, NCoR, and SREBP) were also identi-
fied as regulatory hubs in the control of
MED13-responsive genes. Moreover, mice
with genetic deletion of genes that were down-
regulated in the microarray (Thrsp, Elovl6,
Cidea, Tkt, or PPARg) display resistance to
diet-induced obesity and/or protection against
insulin resistance (Anderson et al., 2009; Jones
et al., 2005; Matsuzaka et al., 2007; Xu et al.,
2002; Zhou et al., 2003). These findings sug-
gest that MED13 functions in the heart to
inhibit expression of select NR-responsive
genes, thereby altering whole-body energy
homeostasis.
Cardiac overexpression of MED13 reduces
fat accumulation in peripheral tissues. We
performed microarray analysis on liver,
gonadal WAT, and BAT from 4-week-old
aMHC-Med13 TG mice and WT littermates
(Figure S4). Panther analysis of the genes
regulated greater than 2-fold revealed that
genes associated with metabolic processes
were the most strongly affected in cardiac
and noncardiac tissues of aMHC-Med13 TG
mice (Thomas et al., 2006).
MED13 Modulates TH-Dependent
Responses
Because MED13 repressed numerous TH-
responsive genes in the heart, we performed
a TH reporter assay to determine whetherMED13 regulates TR activity. MED13 inhibited activation of
a synthetic TH response element (TRE) in the presence of
exogenous TRb by 80% in the presence or absence of TH
(T3) and inhibited promoter activity of the TH-responsive protein
(Thrsp) gene, which was also downregulated by MED13 in vivo
(Figures 5A and 5B). We conclude that MED13 suppresses
TRb transcriptional activation independently of TH.
Figure 5. Modulation of TH Actions by MED13
(A) Inhibition of TRE reporter by Med13 in the presence or absence of T3.
Data are presented as relative luciferase activation. Each data point represents
the average of triplicate transfections from three independent experiments.
#p < 0.05 versus Med13(0 ng) – T3; *p < 0.05 versus Med13(0 ng) + T3.
(B) Luciferase assays measuring pGL2, TRE, or the Thrsp promoter activity in
the presence or absence of Med13. Assays were performed as described in
(A). n = 4.
(C and D) Cardiac fractional shortening and heart rate as measured by
transthoracic echocardiography in aMHC-Med13 TG andWTmice at baseline
or following 2 weeks of PTU treatment. n = 8–10.
(E–G) Quantitative RT-PCR analysis of cardiac mRNA expression from aMHC-
Med13 TG andWTmice on NC or following 2 weeks of PTU treatment. n = 3–4.
Data are represented as mean ± SEM. *p < 0.05.To further investigate the impact of MED13 on TH responsive-
ness of the heart, we examined whether aMHC-Med13 trans-
genic mice displayed an altered response to hypothyroidism.
Treatment with propylthiouracil (PTU), an inhibitor of T3 biosyn-
thesis, reduces cardiac function in WT mice. In contrast, aMHC-
Med13 TG mice were resistant to the PTU-dependent decrease
in contractility, as determined by echocardiography (Figure 5C),
consistent with a hyperthyroid-like state. Elevated heart rate is
a common consequence of enhanced systemic TH signaling;
however, aMHC-Med13 TG mice did not show differences in
heart rate compared to WT mice (Figure 5D). In the adult rodent
heart, upregulation of b-MHC is a sensitive marker of hypothy-
roidism and is blocked by T3 signaling. In miR-208a/ mice,a- to b-MHC switching is blunted in response to PTU treatment
(van Rooij et al., 2007), whereas a- and b-MHC expression was
altered comparably in WT and aMHC-Med13 TG treated with
PTU (Figures 5F–5G), indicating that MED13 does not target all
TR-responsive genes and only a subset of miR-208a functions
are mediated by its regulation of MED13. Atrial natriuretic factor
(ANF), a cardiac stress marker, was elevated to comparable
levels inWT and aMHC-Med13 TGmice in response to PTU (Fig-
ure 5G). Taken together, these findings suggest that MED13
expression in the heart results in a hypermetabolic state due,
in part, to altered TH responses.
Cardiac Deletion of Med13 Enhances Susceptibility
to Obesity
In light of the dramatic effect of cardiac overexpression of
MED13 on global metabolism, we generated mice with a condi-
tional Med13 loss-of-function allele. Deletion of exons 7 and 8
results in a frameshift and loss of a majority of the MED13 coding
sequence, including the putative NLS, NR bindingmotifs, leucine
zipper, and FoxO-like domain (Figures S5A and S5B). Cardiac-
specific deletion of MED13 using aMHC-Cre had no effect on
survival or cardiac function in adult mice (Figure S5C).
To assess the potential metabolic consequences of cardiac
MED13 loss of function, we placed Med13 cardiac knockout
(cKO) mice on HF diet at 6 weeks of age. The Med13 cKO
mice weighed the same as their WT littermates at the onset of
the study but gained significantly more weight beginning within
the first week on HF diet and continuing thereafter (Figures 6A
and 6B). After 6 weeks on HF diet, we observed a small but
statistically significant increase in lean mass and a dramatic
increase in fat mass in the Med13 cKO mice compared to
Med13fl/fl littermates on HF diet (Figure 6C). Heart weight/body
weight ratios were not significantly different in Med13 cKO
mice compared to Med13fl/fl controls (Figure 6D).
Med13 cKO mice had significantly larger visceral white
adipose, subscapular fat, and liver mass than controls on HF
diet (Figures 6E–6H and S5K). Histological analysis of these
tissues revealed an increase in lipid accumulation in the Med13
cKO versusMed13fl/fl mice (Figures 6F and 6I). Liver triglycerides
as well as serum triglycerides, cholesterol, and blood glucose
levels were also elevated in the Med13 cKOs (Figures 6J–6N).
Fasting insulin levels in theMed13 cKOmice were highly variable
but were dramatically increased, as were leptin levels (Figures
6O and 6P). Thus, cardiac deletion of MED13 perturbs whole-
body metabolism, enhancing sensitivity to HF diet, a phenotype
opposite that of Med13 transgenic or antimiR-208a-treated
mice.
DISCUSSION
The results of this study demonstrate that MED13, a regulatory
subunit of theMediator complex, functions in the heart to control
metabolic homeostasis and energy expenditure in mice.
Elevated cardiac expression of MED13 by transgenic overex-
pression or pharmacologic inhibition of miR-208a enhances
metabolic rate, confers resistance to obesity, improves insulin
sensitivity, and lowers plasma lipid levels. Conversely, cardiac-
specific deletion of MED13 increases susceptibility to metabolicCell 149, 671–683, April 27, 2012 ª2012 Elsevier Inc. 677
Figure 6. Cardiac Deletion of Med13 Enhances Susceptibility to Obesity
Analysis of male Med13fl/fl aMHC-cre (cKO) mice and Med13fl/fl littermates (fl/fl) on HF diet (HF) for 6 weeks.
(A) Pictures of Med13fl/fl aMHC-cre and Med13fl/fl mice.
(B) Growth curves and percentage increase in body weight. n = 8–10.
(C) Body compositionmeasuredbyNMR todetermine fatmass and lean tissuemass ofMed13fl/flaMHC-cre andMed13fl/flmice following 6weeks onHF. n=8–10.
(D) Heart weight/body weight ratio. n = 8–10.
(E) Weight of visceral WAT and subscapular fat. n = 8–10.
(F) H&E stained visceral WAT and BAT. Scale bar, 40 mm.
(G) Cell size of visceral WAT. n = 5.
(H) Liver mass. n = 8–10.
(I) Oil red O stained liver. Scale bar, 40 mm.
(J and K) Liver and serum triglyceride content. n = 6–8.
(L) Serum cholesterol levels. n = 6–8.
(M) Glucose tolerance test (GTT). n = 6–8.
(N) Area under the curve for the GTT. n = 6–8.
(O and P) Fasting insulin and leptin levels. n = 6.
Data are represented as mean ± SEM. *p < 0.05.syndrome and severe obesity. These findings reveal an impor-
tant role of the heart in regulation of systemic metabolism and
identify MED13 and miR-208a as central components of this
metabolic regulatory mechanism (Figure 7).678 Cell 149, 671–683, April 27, 2012 ª2012 Elsevier Inc.Cardiac Control of Energy Homeostasis by MED13
The Mediator complex links gene-specific transcription factors
with the basal transcriptional machinery (Ito and Roeder,
2001). The kinase submodule of Mediator, comprised of
Figure 7. Model of Cardiac Dependent
Regulation of Energy Homeostasis
MED13-dependent regulation of select Mediator-
dependent metabolic genes in the heart governs
global energy expenditure. Modulation of MED13
expression levels in the heart by the cardiac-
specific miR-208a results in an altered metabolic
state while independently regulating myosin
switching in the heart in response to cardiac stress.MED12, MED13, CDK8, and cyclin c, represses expression of
select sets of target genes by interfering with the association
of Mediator and RNA polymerase II (Knuesel et al., 2009). There
is also evidence for activation of certain genes by the kinase
submodule (Alarco´n et al., 2009; Belakavadi and Fondell, 2010;
Conaway and Conaway, 2011; Donner et al., 2007).
Though the importance of the Mediator complex in the
control of gene transcription has been well established from
in vitro transcription assays (Conaway and Conaway, 2011;
Malik and Roeder, 2010), determination of the functions of
this complex in adult tissues has been hindered by the fact
that all mutant alleles of Mediator subunits analyzed thus far
in mice result in early lethality. To date, no functions have
been ascribed to MED13 in any mammalian tissues nor have
potential functions of any components of the Mediator complex
been analyzed in the heart. Intriguingly, humans with mutations
in MED12 exhibit hypothyroidism and are predisposed to
obesity (Philibert et al., 2002), suggesting that MED12 exerts
metabolic functions similar to those that we have discovered
for MED13.
Through cardiac-specific gain and loss of function of MED13
in mice, our results highlight a central role of this Mediator
subunit in governance of metabolism via the control of energy
expenditure pathways. Our finding that MED13 deficiency in
the heart enhances obesity in mice on HF diet is consistent
with a recent report that MED13 deficiency in Drosophila causes
enhanced lipid accumulation in the fat body (Pospisilik et al.,
2010) and suggests an evolutionarily conserved role for
MED13 in the control of metabolic homeostasis by striated
muscles of metazoans. Deletion of MED1 in skeletal muscle of
mice confers resistance to diet-induced obesity (Chen et al.,
2010), analogous to the phenotype that we observed with over-
expression of MED13 in the heart. MED1, a core component of
the Mediator complex, controls transcriptional activation by
numerous NRs (Ge et al., 2002; Ito et al., 2000; Malik et al.,
2004). MED13 has not been shown to directly interact with
NRs. MED13 is thought to function as a repressor by sterically
hindering the association of RNA polymerase II with the core
Mediator complex. Therefore, the actions of MED13 on NRsCell 149, 671–6are consistent with the opposing influ-
ences of MED13 on MED1, which does
directly bind to NRs (Knuesel et al., 2009).
Modulation of Cardiac NR Signaling
by MED13
TH is a major determinant of metabolic
rate, energy expenditure, and cardiaccontractility (Song et al., 2011). The global phenotype resulting
from cardiac overexpression of MED13 is similar to that of
enhanced TH signaling, which is associated with increased
energy expenditure and resistance to fat accumulation in mice
and humans (Watanabe et al., 2006). However, only a subset
of TH-dependent genes is modulated in response to MED13
overexpression in the heart. TH stimulates and represses TR-
dependent genes depending on transcriptional cofactors and
intracellular signals (Fondell et al., 1999). Consistent with a
repressive influence, MED13 blocked transcription of TRb
reporter genes in vitro, and transgenic overexpression of
MED13 in the heart suppressed a broad collection of TR and
NR target genes that are involved in energy balance. Among
the genes downregulated by MED13, deletion of Thrsp, Tkt,
Cidea, and Pparg in mice results in resistance to diet-induced
obesity (Anderson et al., 2009; Jones et al., 2005; Xu et al.,
2002; Zhou et al., 2003), as we observed in response to cardiac
overexpression ofMED13. Elovl6 andKng1, which are repressed
by MED13, modulate insulin and glucose homeostasis (Matsu-
zaka et al., 2007; Wu et al., 2010).
In addition to regulating a subset of TR targets, gene network
analysis indicates a role for MED13 in the control of other
transcriptional regulators of lipid biosynthesis and metabolism,
including NCoR1, SREBP, LXR, RXR, and PPARg. It is notable
in this regard that inhibition of SREBP, RXR, and PPARg amelio-
rates diet-induced obesity and type 2 diabetes (Huss and Kelly,
2004; Jones et al., 2005; Yang et al., 2006). Conversely, cardiac-
specific overexpression of PPARa causes metabolic cardiomy-
opathy and hepatic insulin resistance (Finck et al., 2002). Thus,
MED13 appears to function in the heart as a master regulator
of the transcriptional circuitry that is responsible for metabolic
homeostasis by suppressing the actions of multiple metabolic
regulators.
Modulation of Energy Homeostasis by miR-208a
Pharmacologic inactivation of miR-208a, which is cardiac
specific, through systemic delivery of an antimiR confers an
enhanced metabolic phenotype analogous to that of mice with
cardiac overexpression of MED13, suggesting that MED13 is83, April 27, 2012 ª2012 Elsevier Inc. 679
a key effector of the metabolic effects of miR-208a inhibition.
However, there are also some important distinctions between
the phenotypic consequences of miR-208a inhibition and
MED13 overexpression. In particular, mice lacking miR-208a
are resistant to pathological cardiac remodeling and fail to
upregulate b-MHC in response to stress or hypothyroidism
(Callis et al., 2009; van Rooij et al., 2007), whereas MED13
overexpression does not alter b-MHC expression in response
to hypothyroidism. These findings suggest that miR-208a
acts through multiple downstream targets to control metabolic
homeostasis and myosin switching independently (Figure 7),
with MED13 dedicated to the metabolic functions of miR-208a.
In this regard, miR-208a, like other miRNAs, has numerous
targets. Thus, although our results strongly implicate MED13 in
the metabolic actions of miR-208a in the heart, other targets
undoubtedly also contribute to this activity of miR-208a.
miR-208a belongs to a family of miRNAs (referred to as Myo-
miRs) that includes miR-208b and miR-499, encoded by the
b-MHC and Myh7b genes, respectively. In contrast to a-MHC
and miR-208a, which are expressed specifically in the heart,
miR-208b and miR-499 and their host myosin genes are also ex-
pressed in slow skeletal muscle (van Rooij et al., 2009). It will be
of interest to determine whether these miRNAs act through
MED13 in skeletal muscle to control metabolic homeostasis.
Especially intriguing is the ability of myosin genes, which encode
the major contractile proteins of striated muscles, to modulate
such broad-ranging processes as cardiac contractility, stress
responsiveness, and metabolism via the MyomiRs encoded by
their introns.
Cardiac Regulation of Energy Homeostasis
The liver, adipose tissue, and skeletal muscle are well known to
function as the major tissue regulators of whole-body energy
expenditure, metabolism, and glucose homeostasis. Our find-
ings demonstrate that the heart, which has the highest rate of
oxygen consumption per gram of any tissue in the body (Rolfe
and Brown, 1997), plays an important role in the control of energy
homeostasis and adiposity through a mechanism involving
MED13 and miR-208a. Mice with elevated cardiac expression
ofMED13 show normal food intake but display increased oxygen
consumption and carbon dioxide production, indicative of
increased energy expenditure. Conversely, cardiac deletion of
MED13 results in a dramatic increase in lipid accumulation
without alterations in food intake. Changes in energy consump-
tion can lead to alterations in thermogenesis. However, MED13
cardiac gain of function did not alter the ability to maintain core
body temperature in mice. The enhanced whole-body energy
expenditure resulting from cardiac overexpression of MED13
may result from suppression of metabolic genes in the heart
and consequent compensatory metabolic activity in noncardiac
tissues. Alternatively, or in addition, MED13 may control
systemic energy consumption and storage through a cardiac-
derived paracrine factor acting on distal tissues either directly
or through secondary targets such as the brain. The heart has
been shown to exert endocrine effects by releasing natriuretic
peptides ANP and BNP (Sengene`s et al., 2000); however, we
did not observe altered expression of ANP or BNP in mice with
MED13 gain or loss of function. Gene analysis of noncardiac680 Cell 149, 671–683, April 27, 2012 ª2012 Elsevier Inc.tissues, WAT, BAT, and liver suggests activation of a metabolic
gene profile that is consistent with the increase in energy expen-
diture in response to cardiac MED13 activity. Considering that
perturbation of cardiac energy metabolism is among the earliest
alterations in the myocardium during the development of dia-
betes (Harmancey et al., 2008), it will be of interest to investigate
the potential involvement of the MED13-miR-208a regulatory
circuit in this disorder.
Therapeutic Implications
TH signaling confers numerous beneficial effects, including in-
creased metabolic rate, lipolysis, cholesterol lowering, improved
glucose homeostasis, and enhanced cardiac function, as seen in
antimiR-208a-treated and aMHC-Med13 TG mice (Crunkhorn
and Patti, 2008; Song et al., 2011; Watanabe et al., 2006).
However, hyperthyroidism is also associated with adverse
effects, such as tachycardia, arrhythmias, muscle wasting, and
elevated body temperature, which we did not observe in these
mice. There have been numerous efforts to develop THmimetics
for enhancing cardiac function and improving metabolic status,
but the adverse side effects of TH stimulation have limited
the usefulness of such compounds (Tancevski et al., 2011).
AntimiR-208a seems to display the beneficial activities of thyro-
mimetics; however, the target of antimiR-208a is cardiac
specific, thereby bypassing potential adverse effects on other
tissues where TH exerts its effects. The apparent metabolic
effects of miR-208a inhibition and MED13 elevation in the heart
suggest that miR-208a inhibitors, in addition to providing benefit
in the setting of cardiac dysfunction, may have therapeutic
usefulness in a variety of metabolic disorders, such as obesity,




Six-week-old, male C57Bl6 mice were injected subcutaneously with 10 mg/kg
of locked nucleic acid (LNA)-modified antimiR dissolved in saline. The LNA-
modified antimiR oligonucleotides were produced at miRagen Therapeutics,
Inc. and were designed to complement miR-208a and a universal control
directed against a C. elegans-specific miRNA (Montgomery et al., 2011). The
mice were injected for 3 consecutive days and were then given a weekly main-
tenance injection throughout the experiment.
Generation of aMHC-Med13 TG Mice
TheMed13 transcript was amplified frommouse heart total RNA usingMed13-
specific primers. Med13 cDNA was cloned into a plasmid containing the
aMHC promoter and human GH (hGH) poly(A)+ signal (Subramaniam et al.,
1991). Transgenic mice were generated by standard techniques and back-
crossed into the C57Bl6 background for six or more generations.
Generation of Med13 Conditional Knockout Mice
Med13 cKO mice were generated by inserting LoxP sites for Cre-mediated
excision flanking exons 7 and 8, as described in the Supplemental Information
(Figure S5).
Plasmids and Transfection Assays
Plasmids containing a TH response element (TRE), TRb, and RXRa were
obtained from Dr. David Mangelsdorf. The Thrsp promoter was cloned from
genomic DNA by PCR and was inserted into the pGL2 vector (Invitrogen).
HEK293 cells were transfected using FuGENE 6 (Roche). Transfections were
performed with 10 ng pCMV lacZ reporter, 50 ng of the luciferase reporter,
15 ng for each nuclear hormone receptor, and 75 ngGFP-MED13 unless other-
wise stated. Luciferase activity and b-galactosidase assays were performed
on cell lysates.
RNA Analysis
RNA was isolated from mouse tissues using TRIzol reagent (Invitrogen).
RT-PCR was performed to generate cDNA. For qPCR, 20 ng of cDNA was
used for each reaction with Taqman or Sybergreen probes and normalized
to 18S. Sequences for the primers were generated using mouse primer depot
software and are listed in Supplemental Information. Microarray analysis
was performed by the University of Texas Southwestern Microarray Core
Facility using the MouseWG-6 v2.0 BeadChips (Illumina) using RNA extracted
from tissues from three 4-week-old WT or aMHC-Med13 TG mice and
subsequently pooled prior to analysis. Data are available at Geoprofiles,
records GSE35902, GSE35903, and GSE35904.
Metabolic Cage Studies
Metabolic cage studies were performed by the University of Texas South-
western Mouse Metabolic Phenotyping Center. Twelve-week-old male mice
on NC were placed in TSE metabolic chambers for an initial 5 day acclimation
period, followed immediately by a 4.5 day experimental period with data
collection. Room temperature for all metabolic studies was maintained at
22C with a 12 hr light/dark cycle. Airflow into the chamber was maintained
at 0.6 l/min, and exhaust air from each chamber was measured for 3 min every
39 min. Oxygen consumption and carbon dioxide production were measured
and normalized to lean body mass. During this time, ambulatory and rearing
activities were also monitored with infrared beams. Food and water intake
were monitored.
NMR
Male mice body composition parameters including fat mass, lean tissuemass,
and water were analyzed using a Bruker Minispec mq10.
Metabolic Assays
Glucose tolerance tests were performed following overnight fasting. Baseline
measurements were taken using an Accu-Chek Compact Plus glucometer
(Roche). Mice were subsequently injected with 1 mg/g glucose intraperitone-
ally. Glucose levels were then measured at 15, 30, 60, and 120 min following
glucose injection. Blood, heart, and liver were collected from 12-week-old
male mice for triglyceride, cholesterol, insulin, and leptin measurements.
Blood was collected using a 1 ml syringe coated in 0.5 M K(2)EDTA, incubated
for 25 min at room temperature followed by centrifugation for 10 min at
5,000 rpm, and serum collected. Insulin and leptin levels were measured by
ELISA assay.
Transthoracic Echocardiography
Cardiac function was evaluated by two-dimensional transthoracic echocardi-
ography on conscious mice using a VisualSonics Vevo2100 imaging system.
All measurements were performed by a single experienced operator blinded
to the mouse genotypes.
Animal Care
Animals were fed standard chow with 4% kcal from fat ad lib unless
otherwise noted. HF diet analyses were done using the 60% kcal from fat
diet or the 10% kcal from fat as the NC control diet (Open Source Diets
D12492i and D12450Bi). Propylthiouracil (PTU) was administered in the
chow at 0.15% for 2 weeks (Harlan Teklad). All animal procedures were
approved by the Institutional Animal Care and Use Committee at UT
Southwestern Medical Center.
Statistics
Values are expressed as the mean ± standard error. Student’s t test was per-
formed for paired analysis. Multiple group analyses were done by using
ANOVA with Bonferroni correction applied for appropriate posthoc analysis.
The null hypothesis was rejected if p < 0.05.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
five figures and can be found with this article online at doi:10.1016/j.cell.
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